Last reviewed · How we verify
Conversion schedule - Week 1
This drug is used to treat hypertension by blocking the action of angiotensin II at its receptor.
This drug is used to treat hypertension by blocking the action of angiotensin II at its receptor. Used for Hypertension.
At a glance
| Generic name | Conversion schedule - Week 1 |
|---|---|
| Also known as | clobazam (Onfi) |
| Sponsor | St. Joseph's Hospital and Medical Center, Phoenix |
| Drug class | Angiotensin II receptor antagonist |
| Target | AT1 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Losartan works by selectively blocking the angiotensin II type 1 (AT1) receptor, which is a key component of the renin-angiotensin-aldosterone system (RAAS). This blockade leads to vasodilation and a decrease in blood pressure.
Approved indications
- Hypertension
Common side effects
- Dizziness
- Headache
- Fatigue
- Cough
- Diarrhea
Key clinical trials
- Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color） (PHASE2)
- Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study (PHASE4)
- Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies (PHASE2)
- A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations (PHASE3)
- Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC (PHASE1, PHASE2)
- Anaemia Correction in Haemodialyzed Patients - Comparative Analysis of Two Erythropoietin Stimulating Agents Schedules (PHASE4)
- Evaluation of Onfi Conversion Therapy Replacing Clonazepam in Patients With Medically Refractory Epilepsy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: